Biohaven Pharmaceutical Holding EPS - Earnings per Share 2016-2022 | BHVN

Biohaven Pharmaceutical Holding annual and quarterly earnings per share history from 2016 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Biohaven Pharmaceutical Holding EPS for the quarter ending March 31, 2022 was $-2.97, a 30.44% decline year-over-year.
  • Biohaven Pharmaceutical Holding EPS for the twelve months ending March 31, 2022 was $-11.79, a 17.32% decline year-over-year.
  • Biohaven Pharmaceutical Holding 2021 annual EPS was $-13.09, a 0.23% increase from 2020.
  • Biohaven Pharmaceutical Holding 2020 annual EPS was $-13.06, a 19.71% increase from 2019.
  • Biohaven Pharmaceutical Holding 2019 annual EPS was $-10.91, a 77.4% increase from 2018.
Biohaven Pharmaceutical Holding Annual EPS
2021 $-13.09
2020 $-13.06
2019 $-10.91
2018 $-6.15
2017 $-5.00
2016 $-5.05
2015 $-0.91
Biohaven Pharmaceutical Holding Quarterly EPS
2022-03-31 $-2.97
2021-12-31 $-2.96
2021-09-30 $-2.63
2021-06-30 $-3.23
2021-03-31 $-4.27
2020-12-31 $-3.64
2020-09-30 $-3.27
2020-06-30 $-3.08
2020-03-31 $-3.07
2019-12-31 $-2.79
2019-09-30 $-2.04
2019-06-30 $-4.67
2019-03-31 $-1.41
2018-12-31 $-1.29
2018-09-30 $-1.53
2018-06-30 $-1.01
2018-03-31 $-2.32
2017-12-31 $-0.29
2017-09-30 $-1.19
2017-06-30 $-1.78
2017-03-31 $-1.74
2016-12-31 $-2.09
2016-09-30 $-2.16
2016-06-30 $-0.55
2016-03-31 $-0.25
2015-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.944B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00